Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 | Synapse
September 10, 2025Open Access
Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Key Points
Characterization of LAG-3 and PD-L1 gene expression highlights unique immune responses in melanoma.
Key findings include expression variations that may inform therapeutic strategies for advanced melanoma.
Data collection involved comprehensive analyses of immune and tumor cell gene expressions related to treatment.
Insights from these biomarker analyses could lead to improved patient outcomes and tailored therapies.
Abstract
Characterization of gene expression associated with (A) LAG-3 and (B) PD-L1 expression on immune and tumor cells.